Cibus sets $200M yearly rice royalty goal as it progresses with global commercialization plan.
Management Insights: Cibus, Inc. reported significant commercialization momentum, focusing on high-value gene-edited traits for rice, with 7 customer agreements signed across the USA and Latin America, potentially leading to over $200 million in annual royalties.
Financial Performance: The company experienced a revenue drop to $615,000 in Q3 2025, down from $1.7 million the previous year, but improved its net loss to ($24.3 million) from ($201.5 million) due to cost reductions and the absence of a goodwill impairment charge.
Outlook and Expansion: Cibus plans to launch rice herbicide tolerance traits commercially in Latin America by 2027, with expectations for initial revenues from these traits in 2026, while also expanding into Asia through a partnership in India.
Analyst Sentiment: Analysts maintained a neutral to positive outlook, focusing on commercialization timelines and regulatory progress, while management expressed confidence in near-term revenue opportunities and operational efficiencies.
Trade with 70% Backtested Accuracy
Analyst Views on CBUS
About CBUS
About the author
Cibus Develops Disease-Resistant Oilseed Varieties
- Project Background: Cibus is participating as a key technology partner in a UK government-funded research project aimed at utilizing its proprietary Rapid Trait Development System™ (RTDS®) to combat Light Leaf Spot disease, which caused an estimated £300 million in yield losses in 2022, highlighting the project's significance for agricultural production.
- Technology Application: By collaborating with the John Innes Centre and the University of Hertfordshire, Cibus applies its gene-editing expertise to develop new oilseed varieties, significantly shortening the time to market for new traits, thereby assisting farmers in tackling increasingly severe disease challenges and enhancing crop economic viability.
- Partnership Composition: The project involves a consortium of 12 industry and academic partners aiming to deliver high-yielding oilseed varieties with durable multi-disease resistance by
Cibus and Interoc Sign LOI for 2027 Market Entry in Latin America
- Market Entry Plan: Cibus and Interoc have signed a non-binding Letter of Intent (LOI) to initiate commercialization in Ecuador and Colombia by 2027, followed by expansion into Peru, Central America, and the Caribbean, marking a significant shift from R&D to market execution in their collaboration.
- Technology Integration: Cibus has successfully integrated herbicide-tolerant traits into Interoc's elite rice germplasm, which is expected to enhance productivity in Latin America by addressing urgent farmer needs against resistant weeds, thereby improving yields.
- Collaboration Potential: The signing of the LOI establishes a framework for commercial sales, with Cibus and Interoc aiming to jointly promote high-performing rice hybrids in key markets, targeting rapid market share growth in rice production areas.
- Sustainable Development Goals: By combining Cibus' gene-editing technologies with Interoc's elite genetics, both companies are committed to enhancing agricultural productivity and advancing sustainable farming practices in Latin America to meet the increasing food demand.
Cibus Advances Gene Editing Legislation in EU for Enhanced Plant Breeding
- Legislative Progress: Cibus welcomes the agreement on the EU's New Genomic Techniques (NGTs) regulatory framework, marking a significant advancement in the company's efforts to innovate gene-edited plants, which is expected to provide European farmers with improved crop varieties.
- Market Opportunities: This agreement offers Cibus legal assurance to develop new plant varieties in the European market, likely driving growth in the company's market share within the agricultural technology sector to meet increasing agricultural demands.
- International Collaboration: Cibus has successfully completed field trials in the UK for its advanced trait in winter oilseed rape, demonstrating the company's leadership in gene editing technology and further enhancing its competitive edge in the European market.
- Strategic Investment: Cibus's technology development aligns with the EU's legislative process, which is expected to create new growth opportunities for the company's product pipeline, particularly in addressing pressing agricultural challenges.
VTI ETF Daily Report—November 25, 2025
Vanguard Total Stock Market ETF Overview: The VTI ETF provides broad exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.
Market Performance: On Monday, VTI rose by 1.21%, while the Nasdaq Composite and S&P 500 increased by 2.7% and 1.5%, respectively, as investor confidence grew ahead of potential Federal Reserve policy easing.
Investment Trends: Despite a slight decline of 0.26% over the past five days, VTI is up 13% year-to-date, with a three-month average trading volume of 4.06 million shares and recent net inflows of $246 million.
Analyst Consensus and Potential: VTI is rated as a Moderate Buy with an average price target of $387.05, suggesting a 17.7% upside, while its Smart Score of seven indicates expected performance in line with the broader market.
Daily Update on VTI ETF – November 24, 2025
VTI Performance Overview: The Vanguard Total Stock Market ETF (VTI) is down 1.74% over the past week but has increased by 13% year-to-date, with a slight gain of 0.21% in pre-market trading on Monday.
Market Context: U.S. stocks, including the Nasdaq Composite and S&P 500, closed higher on Friday, recovering from a previous tech-led selloff, with VTI's trading volume averaging 4.06 million shares over three months.
Technical Analysis and Ratings: VTI has a Neutral rating overall but a Sell signal based on moving averages, currently trading at $323.80, below its 50-day moving average of $327.30.
Analyst Consensus and Holdings: VTI is rated as a Moderate Buy by analysts, with a price target of $392.91 suggesting a 21.3% upside, while it holds 3,488 stocks with varying potential for upside and downside.
VTI ETF Daily Report — November 21, 2025
VTI Overview: The Vanguard Total Stock Market ETF (VTI) provides extensive exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.
Recent Performance: VTI has experienced a 4.86% decline over the past week but is up 13.3% year-to-date, with notable declines in the Nasdaq Composite and S&P 500 due to market uncertainties.
Top Holdings: The ETF's leading holdings include Nvidia (6.69%), Microsoft (5.98%), and Apple (5.87%), with a three-month average trading volume of 4.02 million shares.
Analyst Consensus: VTI is rated as a Moderate Buy by analysts, with a price target suggesting a potential upside of 25%, while its Smart Score indicates it is likely to perform in line with the broader market.
Cibus Develops Disease-Resistant Oilseed Varieties
- Project Background: Cibus is participating as a key technology partner in a UK government-funded research project aimed at utilizing its proprietary Rapid Trait Development System™ (RTDS®) to combat Light Leaf Spot disease, which caused an estimated £300 million in yield losses in 2022, highlighting the project's significance for agricultural production.
- Technology Application: By collaborating with the John Innes Centre and the University of Hertfordshire, Cibus applies its gene-editing expertise to develop new oilseed varieties, significantly shortening the time to market for new traits, thereby assisting farmers in tackling increasingly severe disease challenges and enhancing crop economic viability.
- Partnership Composition: The project involves a consortium of 12 industry and academic partners aiming to deliver high-yielding oilseed varieties with durable multi-disease resistance by
Cibus and Interoc Sign LOI for 2027 Market Entry in Latin America
- Market Entry Plan: Cibus and Interoc have signed a non-binding Letter of Intent (LOI) to initiate commercialization in Ecuador and Colombia by 2027, followed by expansion into Peru, Central America, and the Caribbean, marking a significant shift from R&D to market execution in their collaboration.
- Technology Integration: Cibus has successfully integrated herbicide-tolerant traits into Interoc's elite rice germplasm, which is expected to enhance productivity in Latin America by addressing urgent farmer needs against resistant weeds, thereby improving yields.
- Collaboration Potential: The signing of the LOI establishes a framework for commercial sales, with Cibus and Interoc aiming to jointly promote high-performing rice hybrids in key markets, targeting rapid market share growth in rice production areas.
- Sustainable Development Goals: By combining Cibus' gene-editing technologies with Interoc's elite genetics, both companies are committed to enhancing agricultural productivity and advancing sustainable farming practices in Latin America to meet the increasing food demand.
Cibus Advances Gene Editing Legislation in EU for Enhanced Plant Breeding
- Legislative Progress: Cibus welcomes the agreement on the EU's New Genomic Techniques (NGTs) regulatory framework, marking a significant advancement in the company's efforts to innovate gene-edited plants, which is expected to provide European farmers with improved crop varieties.
- Market Opportunities: This agreement offers Cibus legal assurance to develop new plant varieties in the European market, likely driving growth in the company's market share within the agricultural technology sector to meet increasing agricultural demands.
- International Collaboration: Cibus has successfully completed field trials in the UK for its advanced trait in winter oilseed rape, demonstrating the company's leadership in gene editing technology and further enhancing its competitive edge in the European market.
- Strategic Investment: Cibus's technology development aligns with the EU's legislative process, which is expected to create new growth opportunities for the company's product pipeline, particularly in addressing pressing agricultural challenges.
VTI ETF Daily Report—November 25, 2025
Vanguard Total Stock Market ETF Overview: The VTI ETF provides broad exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.
Market Performance: On Monday, VTI rose by 1.21%, while the Nasdaq Composite and S&P 500 increased by 2.7% and 1.5%, respectively, as investor confidence grew ahead of potential Federal Reserve policy easing.
Investment Trends: Despite a slight decline of 0.26% over the past five days, VTI is up 13% year-to-date, with a three-month average trading volume of 4.06 million shares and recent net inflows of $246 million.
Analyst Consensus and Potential: VTI is rated as a Moderate Buy with an average price target of $387.05, suggesting a 17.7% upside, while its Smart Score of seven indicates expected performance in line with the broader market.
Daily Update on VTI ETF – November 24, 2025
VTI Performance Overview: The Vanguard Total Stock Market ETF (VTI) is down 1.74% over the past week but has increased by 13% year-to-date, with a slight gain of 0.21% in pre-market trading on Monday.
Market Context: U.S. stocks, including the Nasdaq Composite and S&P 500, closed higher on Friday, recovering from a previous tech-led selloff, with VTI's trading volume averaging 4.06 million shares over three months.
Technical Analysis and Ratings: VTI has a Neutral rating overall but a Sell signal based on moving averages, currently trading at $323.80, below its 50-day moving average of $327.30.
Analyst Consensus and Holdings: VTI is rated as a Moderate Buy by analysts, with a price target of $392.91 suggesting a 21.3% upside, while it holds 3,488 stocks with varying potential for upside and downside.
VTI ETF Daily Report — November 21, 2025
VTI Overview: The Vanguard Total Stock Market ETF (VTI) provides extensive exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.
Recent Performance: VTI has experienced a 4.86% decline over the past week but is up 13.3% year-to-date, with notable declines in the Nasdaq Composite and S&P 500 due to market uncertainties.
Top Holdings: The ETF's leading holdings include Nvidia (6.69%), Microsoft (5.98%), and Apple (5.87%), with a three-month average trading volume of 4.02 million shares.
Analyst Consensus: VTI is rated as a Moderate Buy by analysts, with a price target suggesting a potential upside of 25%, while its Smart Score indicates it is likely to perform in line with the broader market.
